Affordable Access

Publisher Website

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks' Glecaprevir/Pibrentasvir Therapy.

  • Andreoni, Massimo1
  • Di Perri, Giovanni2
  • Persico, Marcello3
  • Marcellusi, Andrea4
  • Ethgen, Olivier5, 6
  • Sanchez Gonzalez, Yuri7
  • Bondin, Mark7
  • Zhang, Zhenzhen7
  • De Michina, Antonella8
  • Merolla, Rocco Cosimo Damiano8
  • Craxì, Antonio9
  • 1 University of Tor Vergata, Rome, Italy. [email protected] , (Italy)
  • 2 Department of Clinical Infectious Diseases, University of Turin, Turin, Italy. , (Italy)
  • 3 Internal Medicine and Hepatology Unit, Department of Medicine and Surgery "Scuola Medica Salernitana", University of Salerno, Baronissi, Italy. , (Italy)
  • 4 Center for Economic and International Studies, Faculty of Economics, University of Tor Vergata, Rome, Italy. , (Italy)
  • 5 SERFAN Innovation, Namur, Belgium. , (Belgium)
  • 6 Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium. , (Belgium)
  • 7 AbbVie Inc, North Chicago, IL, USA.
  • 8 AbbVie S.R.L, Rome, Italy. , (Italy)
  • 9 GI and Liver Unit, PROMISE, University of Palermo, Palermo, Italy. , (Italy)
Published Article
Infectious diseases and therapy
Publication Date
Mar 03, 2021
DOI: 10.1007/s40121-021-00410-0
PMID: 33655410


In Italy, hepatitis C virus (HCV) elimination is achievable; however, barriers remain to achieving the World Health Organization's elimination targets, and have become more pronounced with the spread of COVID-19. Glecaprevir/pibrentasvir (G/P) is a direct-acting antiviral therapy for HCV, approved for 8-week treatment in patients without cirrhosis, and with compensated cirrhosis (CC). Previously, 12 weeks of therapy was recommended for patients with CC. Shortened treatment may reduce the burden on healthcare resources, allowing more patients to be treated. This study presents the benefits that 8-week vs 12-week treatment with G/P may have in Italy. A multicohort Markov model was used to assess the collective number of healthcare visits and time on treatment with 8-week vs 12-week G/P in the HCV-infected population of Italy from 2019 to 2030, using healthcare resource data from post-marketing observational studies of G/P. Increased treatment capacity and downstream clinical and economic benefits were also assessed assuming the reallocation of saved healthcare visits to treat more patients. Modeled outcomes showed that by 2030, 8-week treatment saved 27,006 years on therapy compared with 12-week treatment, with 21,065 fewer hepatologist visits. Reallocating these resources to treat more patients could increase capacity to treat 5064 (1.4%) more patients with 8 weeks of G/P, all with CC. This increased treatment capacity would further avoid 2257 cases of end-stage liver disease, 893 liver-related deaths, and provide net savings to the healthcare system of nearly €70 million. The modeled comparisons between 8- and 12-week treatment with G/P show that shorter treatment duration can lead to greater time and resource savings, both in terms of healthcare visits and downstream costs. These benefits have the potential to enable the treatment of more patients to overcome elimination barriers in Italy through programs aimed to engage and treat targeted HCV populations.

Report this publication


Seen <100 times